Athira Pharma, Inc. is advancing a novel, potentially transformative approach for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Unlike other products approved and in ...

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018.

On January 6, the Department of Justice (DOJ) announced that Athira Pharma Inc., a Washington-based biopharmaceutical company, agreed to pay over $4 million to settle allegations it violated the ...

Athira Pharma (ATHA) agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act by failing to report allegations of research misconduct to the National Institutes of ...

From what we can see, insiders were net buyers in Athira Pharma, Inc.'s ( NASDAQ:ATHA ) during the past 12 months. That... BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma ...